Citi Pharma secures CCP approval to acquire 100% stake in Pakheim International Pharma

Citi Pharma has received clearance from the Competition Commission of Pakistan for its planned purchase of the entire share capital of Pakheim International Pharma, according to a notice filed with the PSX on Monday. The regulator's order, dated October 9, 2026, concluded that the deal raises no competition concerns, though the company still needs to complete remaining legal and regulatory steps before closing. Citi Pharma said it will provide further updates as those requirements are finished.

The pharmaceutical maker first announced the deal in May 2026, when it said Pakheim earned roughly Rs500 million in annual revenue. Citi Pharma aims to lift that figure tenfold to Rs5 billion within five years, through a wider product range, stronger distribution and more investment in plants. The share purchase agreement was signed on May 6, 2026, with payments extending to December 31, 2026 and expected to come from operating cash flows.

The company also expects the deal to boost its active pharmaceutical ingredients business by supplying raw materials to Pakheim's factories, which it says should lift API sales and improve use of its existing capacity. Citi Pharma, incorporated in 2012, deals in drugs, medical chemicals and botanical goods, and has been listed on the PSX since July 9, 2021.